The gut microbiome is crucial to human health. The microbes found in this complex ecosystem perform important functions to keep us healthy. The loss of these microbes leads to a loss in their function and, ultimately, can lead to disease. BiomeBank, a clinical-stage biotechnology company, is on a mission to treat and prevent disease by restoring the gut microbial ecology.
BiomeBank's donor-derived microbiome therapy, provides an alternative way of treating conditions like C. difficile infection than traditional treatment. With its approval by Australian regulators in 2022, BiomeBank became the first company to gain regulatory approval for a donor-derived microbiome drug product in the world.
